secwatch / observer
8-K filed April 6, 2023, 7:59 PM ET CIK 0000849636
other material confidence high sentiment neutral materiality 0.25

RespireRx raises $25,000 via sale of 250 shares of Series I 8% Redeemable Preferred Stock

RespireRx Pharmaceuticals Inc.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

RespireRx Pharmaceuticals Inc.: Filed Certificate of Designation for Series I Preferred Stock to amend the certificate of incorporation, setting forth preferences, rights and limitations of the new series (effective 2023-04-03).

Change
charter amendment
Effective
2023-04-03
Exact text from the filing
On April 3, 2023, the Company filed a Certificate of Designation, Preferences, Rights and Limitations of its Series I Preferred Stock, also referred to herein as the “Certificate” with the Secretary of State of the State of Delaware to amend the Company’s certificate of incorporation.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

RespireRx Pharmaceuticals Inc. entered into Securities Purchase Agreement with two individual accredited investors investing jointly valued at $25,000.00 (effective 2023-04-05).

Action
entry
Agreement
equity purchase
Counterparty
two individual accredited investors investing jointly
Value
$25,000.00
Effective
2023-04-05
Exact text from the filing
On April 5, 2023, RespireRx Pharmaceuticals Inc. (the “Company” or the “Corporation”) entered into a securities purchase agreement (“Securities Purchase Agreement) with two individual accredited investors investing jointly (“Investors”). Pursuant to the terms of the Securities Purchase Agreement, the investors invested $25,000.00 for 250 shares of Series I 8% Redeemable Preferred Stock
View on SEC.gov

Browse all governance changes →

Source: SEC EDGAR
accession 0001493152-23-011123
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.